Jigar Patel says 25,700 will act as immediate support and 26,100 as resistance. He recommends short-term stocks include Oil ...

Vertex has enacted or continued several key launches in 2025. These include its new once-daily triple-combination therapy for ...

A Relative Strength Rating upgrade for Corcept Therapeutics shows improving technical performance. Will it continue?

Kimberly-Clark agrees to buy Tylenol maker Kenvue in a cash-and-stock deal valued at about $48.7 billion, including debt.